Peprazom (Esomeprazole) Dosing
For adults with GERD, start with esomeprazole 20 mg once daily taken 30-60 minutes before a meal for 4-8 weeks; for pediatric patients aged 1-17 years, use weight-based dosing of 0.7-3.3 mg/kg/day. 1
Adult Dosing by Indication
The FDA-approved dosing varies by clinical indication 1:
Standard GERD Treatment
- Symptomatic GERD: 20 mg once daily for 4 weeks (extend to 8 weeks if symptoms persist)
- Erosive esophagitis (healing): 20-40 mg once daily for 4-8 weeks
- Maintenance of healed erosive esophagitis: 20 mg once daily (studies support up to 6 months)
Other Indications
- NSAID-associated gastric ulcer prevention: 20-40 mg once daily
- H. pylori eradication (triple therapy): 40 mg once daily for 10 days with amoxicillin 1000 mg twice daily and clarithromycin 500 mg twice daily
- Zollinger-Ellison syndrome: Up to 240 mg/day as clinically indicated
Critical Timing
Take esomeprazole at least 1 hour before meals 1. The 2022 AGA guideline emphasizes counseling patients to take PPIs 30-60 minutes prior to a meal for optimal efficacy 2.
Pediatric Dosing
Ages 12-17 Years
- Erosive esophagitis: 20 mg or 40 mg once daily for 4-8 weeks
- Symptomatic GERD: 20 mg once daily for 4 weeks 1
Ages 1-11 Years
The 2013 AAP Pediatrics guideline provides weight-based dosing of 0.7-3.3 mg/kg/day 3. This wide range reflects individual variability in response, with studies showing effective dosing from 0.7 to 3.3 mg/kg daily based on symptom improvement and pH monitoring 3.
Important caveat: PPIs are FDA-approved for children ≥1 year old. In infants, placebo-controlled trials have NOT demonstrated superiority over placebo for reducing irritability 3. The AAP strongly cautions against overuse in infants due to increased risk of lower respiratory tract infections, gastroenteritis, and candidemia 3.
Dose Escalation Strategy
If inadequate response after 4-8 weeks 2:
- Increase to twice daily dosing, OR
- Switch to a more potent PPI (esomeprazole is already less metabolized through CYP2C19, making it a preferred choice)
The 2022 AGA guideline recommends reassessing after the initial trial and tapering to the lowest effective dose once adequate response is achieved 2.
Special Populations
Severe Hepatic Impairment (Child-Pugh Class C)
Maximum 20 mg once daily 1. Patients with severe liver disease have 2-3 times higher drug exposure.
Renal Impairment
No dose adjustment needed—less than 1% is excreted unchanged in urine 1.
Elderly
No dose adjustment required despite 25% higher AUC 1.
Administration Options
For patients unable to swallow capsules 1:
- Open capsule and sprinkle granules on 1 tablespoon of applesauce (must be room temperature, soft enough to swallow without chewing)
- Administer immediately; do not store mixture
- Do not chew or crush granules
For nasogastric tube administration:
- Mix granules with 50 mL water in 60 mL catheter-tipped syringe
- Shake vigorously for 15 seconds
- Administer immediately through NG tube
- Flush with additional water
Common Pitfalls
- Timing error: Taking with or after meals reduces efficacy significantly
- Infant overuse: No proven benefit for uncomplicated reflux/irritability in infants <1 year
- Indefinite continuation without reassessment: The AGA recommends evaluating appropriateness within 12 months for unproven GERD and offering objective testing (endoscopy with pH monitoring off PPI) to establish need for long-term therapy 2
- Crushing capsules: This destroys the delayed-release coating and renders the drug ineffective